O
IONS icon

OrbiMed’s Ionis Pharmaceuticals IONS Stock Holding History

OrbiMed’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,540,136
Closed -$76.6M – 108
2025
Q1 		$76.6M Sell
2,540,136
-277,211
-10% -$9.08M 1.83% 18
2024
Q4 		$98.5M Buy
2,817,347
+492,900
+21% +$18.4M 2.03% 13
2024
Q3 		$93.1M Sell
2,324,447
-47,886
-2% -$2.23M 1.69% 17
2024
Q2 		$113M Buy
2,372,333
+359,300
+18% +$14.7M 2.23% 11
2024
Q1 		$87.3M Sell
2,013,033
-51,764
-3% -$2.47M 1.6% 17
2023
Q4 		$104M Sell
2,064,797
-104,703
-5% -$5.02M 2.09% 12
2023
Q3 		$98.4M Hold
2,169,500
– – 2.09% 11
2023
Q2 		$89M Buy
2,169,500
+45,000
+2% +$1.73M 1.61% 16
2023
Q1 		$75.9M Buy
2,124,500
+130,900
+7% +$4.92M 1.49% 19
2022
Q4 		$75.3M Buy
1,993,600
+1,224,700
+159% +$51.5M 1.44% 23
2022
Q3 		$34K Buy
768,900
+315,500
+70% +$13.3M 0.63% 54
2022
Q2 		$16.8K Buy
+453,400
New +$17.1M 0.3% 69
2020
Q1 		– Sell
-106,900
Closed -$6.46M – 152
2019
Q4 		$6.46M Buy
+106,900
New +$6.37M 0.09% 95

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed's IONS Position: Q2 2025 in Review

OrbiMed sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 2,540,136 shares — an estimated $76.6M sold.

OrbiMed first reported a position in IONS in Q4 2019 and held it in 13 quarters. The position peaked at $113M in Q2 2024. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

  • OrbiMed reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • OrbiMed sold 2,540,136 Ionis Pharmaceuticals shares in Q2 2025, an estimated $76.6M.
  • OrbiMed first reported a position in Ionis Pharmaceuticals in Q4 2019 and held it in 13 quarters.
  • OrbiMed's Ionis Pharmaceuticals position peaked at $113M in Q2 2024.
  • 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.